|

Cardiometabolic evalUation REgistry of Heart Failure

RECRUITINGSponsored by Ruijin Hospital
Actively Recruiting
SponsorRuijin Hospital
Started2015-01-01
Est. completion2027-05-31
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

This is a combined retrospective-prospective observational cohort study investigating the role of systemic and local cardiometabolic risk factors in cardiac structural/functional remodeling and clinical outcomes among heart failure (HF) patients. The study integrates retrospective clinical data (from the past 10 years) and prospective longitudinal follow-up (5 years) of HF patients across HF with reduced (HFrEF), mildly-reduced (HFmrEF), preserved (HFpEF) and improved ejection fraction (HFimpEF) phenotypes. Systemic metabolic factors (e.g., blood lipid profiles, glycemic levels, insulin resistance) and local factors (e.g., epicardial adipose tissue \[EAT\], perivascular adipose tissue \[PVAT\]) will be analyzed for their associations with changes in cardiac geometrics and function, dynamic transitions between HF phenotypes, as well as the occurrence of major adverse cardiovascular events (MACEs). The study seeks to advance risk stratification by integrated evaluation of cardiometabolic profiles so as to refine personalized cures in HF management.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Age ≥ 18 years
2. Chronic HF (NYHA II\~IV), including:

   * HFrEF (HF with reduced ejection fraction): ① HF symptoms±signs ; ② LVEF≤40%.
   * HFimpEF (HF with improved ejection fraction): ① HF symptoms±signs; ② previous LVEF ≤ 40% and a follow-up measurement of LVEF \>40%.
   * HFmrEF (HF with mildly reduced ejection fraction): ① HF symptoms±signs; ② LVEF 41%\~49%.
   * HFpEF (HF with preserved ejection fraction): ① HF symptoms±signs; ② LVEF ≥50%; ③ objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of LV diastolic dysfunction/raised LV filling pressures, including raised natriuretic peptide.

Exclusion Criteria:

1. Estimated survival ≤ 1 year.
2. Pregnant or lactation, or have the intention to give birth within one year.
3. Poor compliance, unable to follow-up.
4. Mental or physical status not allowing written informed consent.
5. Unwillingness to give informed consent.

Conditions4

Heart DiseaseHeart FailureMetabolic Cardiovascular SyndromeMetabolic Diseases

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.